The week in pharma: action, reaction and insight – week to April 26, 2024

28 April 2024

By Barbara Obstoj-Cardwell. Editor

M&A news last week saw US biotech Incyte announce a $750 million offer to acquire Escient Pharmaceuticals and its immunology candidates EP262 and EP547. On the regulatory front, Travere Therapeutics last week gained European conditional approval for its IgA nephropathy drug Filspari. Regeneron signed a collaboration with fellow USA-based biotech Mammoth Biosciences, a developer of CRISPR drugs, worth around $100 million. Also of note, Swiss pharma giant Novartis presented Phase III data at the World Congress of Nephrology on its Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH).

Incyte acquires Escient Pharma, bolstering derma and I&I portfolio

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK